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Human cytomegalovirus (HCMV), a common herpes virus, has been reported to be a risk
factor for many diseases, including malignant diseases such as glioma, neuroblastoma, and
breast cancer. Some of the HCMV-associated diseases (e.g., glioma) are rare.The question
arises: how could a common virus be associated with uncommon diseases? Interactions
between a major gene complex of the human immune system and a viral immunoeva-
sion strategy – a probable mechanism of their co-evolutionary adaptation – may shed light
on this paradox. To ensure its survival, HCMV has evolved sophisticated immunoevasion
strategies. One strategy involves encoding decoy Fcγ receptors (FcγR), which may enable
the virus to evade host immunosurveillance by avoiding the Fcγ-mediated effector con-
sequences of anti-HCMV IgG antibody binding. Immunoglobulin G1 proteins expressing
GM (γ marker) alleles 3 and 17 have differential affinity to the HCMVTRL11/IRL11-encoded
FcγR, and thus act as effect modifiers of HCMV-associated malignancies. The high affinity
GM 3 allele has been shown to be a risk factor for neuroblastoma, glioma, and breast
cancer. Additional studies involving other viral FcγRs as well as GM alleles expressed on
other IgG subclasses are warranted.
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INTRODUCTION
Immunoglobulin (Ig) GM (γ marker) allotypes are encoded by
three very closely linked genes – Ig heavy chain G1 (IGHG1),
IGHG2, and IGHG3 – on chromosome 14q32. There are currently
18 serologically testable GM specificities – four on γ1 (1/a, 2/x,
3/f, 17/z), one on γ2 (23/n), and 13 on γ3 (5/b1, 6/c3, 10/b5,
11/b0, 13/b3, 14/b4, 15/s, 16/t, 21/g1, 24/c5, 26/u, 27/v, 28/g5). Ig
γ4 chains do not express γ4-specific unique allotypes, but they
do express isoallotypes – determinants that behave as alleles in
one IgG subclass (allotypes) but are also expressed in all mole-
cules of at least one other subclass (isotypes). With the exception
of allelic GM 3 and GM 17 determinants expressed in the Fd
region, all other GM alleles are expressed in the Fc region of γ
chains (Figure 1). Linkage disequilibrium in the GM gene com-
plex within a racial group is almost absolute and the determinants
are transmitted as a group – haplotypes. Each major race has
a distinct array of several GM haplotypes (1–3). There are also
qualitative differences in the distribution of GM allotypes among
various racial/ethnic groups. For instance, GM 3 is not commonly
found in people of African descent or GM 6 in those of Euro-
pean ancestry; GM 1 is polymorphic only in people of European
ancestry.
Population genetic properties of the GM gene complex –
marked differences in allele frequencies of among races, strong
linkage disequilibrium within a race, and racially restricted occur-
rence of GM haplotypes – collectively suggest that differential
selection over many generations may have played an important
role in the maintenance of polymorphism at GM loci. As first
suggested by Haldane (4) and recently emphasized by others (5),
major infectious diseases have been the principal selective forces
of natural selection in humans. GM allotypes, as likely targets of
these selective forces, could contribute to the outcome of infec-
tion via allotype-restricted differential immunity to the infectious
pathogens.
This mini review will discuss how GM alleles influence certain
immunoevasion strategies of human cytomegalovirus (HCMV)
and thus act as potential effect modifiers of some HCMV-
associated malignant diseases. Other putative mechanisms of GM
gene involvement in immunity to self and non-self antigens are
also discussed.
GM ALLELES AND CYTOMEGALOVIRUS IMMUNOEVASION
Human cytomegalovirus has evolved highly sophisticated strate-
gies for evading host immunosurveillance. One strategy involves
generating proteins that have functional properties of the Fcγ
receptor (FcγR) (6), which may enable the virus to evade host
immunosurveillance by avoiding the effector consequences of
anti-HCMV IgG antibody binding, such as antibody-dependent
cellular cytotoxicity (ADCC), antibody-dependent cellular phago-
cytosis, and antibody-dependent complement-dependent cyto-
toxicity. The HCMV-encoded FcγR may interfere with Fcγ-
mediated effector functions by bipolar bridging, in which the
Fab part of the anti-HCMV IgG antibody (paratope) binds to
its antigenic target (epitope) on the virus, whereas the Fcγ part
of the antibody binds to the FcγR-like binding site on the viral
protein, thus offering survival advantage to the virus by sterically
hindering the access of (cellular) FcγR-expressing effector cells to
the HCMV-infected cells.
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FIGURE 1 | Diagrammatic representation of an IgG molecule with a κ
light chain. Most GM alleles are expressed in the CH2 and CH3 domains.
Certain GM alleles appear to modulate this immunoevasion
strategy of HCMV (7). We have shown that HCMVTRL11/IRL11-
encoded FcγR has significantly higher affinity for IgG1 proteins
expressing the GM 3+,1−,2− allotypes than for those expressing
the allelic GM 17+,1+,2+ allotypes (p= 0.0005). Higher affin-
ity of GM 3+,1−,2− expressing IgG1 to the TRL11-encoded
FcγR would imply that subjects with GM 3+,1−,2− allotypes
would be more likely to have their Fc domains scavenged, thereby
reducing their immunological competence to eliminate the virus
through ADCC and other Fc-mediated effector mechanisms. Con-
sequently, subjects possessing the GM 3+ ,1−,2− allotypes would
be expected to be at an increased risk – while those carrying the
GM 17+,1+,2+ allotypes (because of the lower affinity to the
viral FcγR) at a reduced risk – of developing HCMV-associated
diseases. These results are reminiscent of those reported for the
herpes simplex virus type 1 (HSV1)-encoded FcγR; the bind-
ing pattern, however, is reversed: the HSV1-encoded FcγR binds
much more strongly to the IgG molecule carrying the GM 1,17
allele than the one carrying the GM 3 allele (8). The contrast-
ing binding patterns of the two viral FcγRs shed light on the
nature of the evolutionary mechanism that maintains genetic
polymorphism at the γ1 locus. Since IgG antibodies expressing
both alleles/haplotypes would be expected to be protective factors
due to their modulating effects against the immunoevasion strate-
gies of HCMV and HSV1, the heterozygotes at this locus would
have advantage over homozygotes, resulting in the persistence of
both alleles/haplotypes in the population. This would represent
an example of balancing selection for the human adaptation of
herpes viruses.
A brief review of the studies that suggest a role for GM genes
as effect modifiers of HCMV-associated malignancies is presented
below.
CYTOMEGALOVIRUS, GLIOMAS, AND GM ALLELES
Human cytomegalovirus is not considered an oncogenic virus at
present, but several features of HCMV biology overlap with the
essential alterations of cell physiology, including tumor microen-
vironment, that are hallmarks of cancer, as enunciated by Hanahan
and Weinberg (9). In 2002, Cobbs and colleagues, for the first time,
presented evidence that implicated this virus in gliomagenesis
(10). Since then numerous studies have documented the pres-
ence of HCMV DNA, RNA, and protein in the majority of human
gliomas, and HCMV-based therapies appear promising (11–13).
Although the current consensus in the field is that HCMV is
an active promoter or oncomodulator of gliomagenesis, it is clear
that among exposed individuals, not everyone is equally likely to
develop HCMV-associated glioma, implying the presence of host
genetic factors that might modulate immunity to this virus. Ig
GM genes are good candidates, as they are involved in immunity
to several viruses, including HCMV (14–23). These observations –
and especially the modulating influence of GM alleles on HCMV’s
immunoevasion strategies discussed above – led us to hypothesize
that these polymorphic determinants might be risk factors for the
development of glioma (24).
Using a case–control design, we tested this hypothesis in a group
of 120 glioma patients and 133 random blood donors as controls.
Both patients and controls were unrelated Caucasians from Por-
tugal. DNA from the study subjects was typed for GM 3 and 17
alleles. Genotype frequencies were in Hardy–Weinberg equilib-
rium in both groups. Odds ratios (OR) for the GM genotypes
for the risk of glioma were estimated by unconditional multivari-
ate logistic regression analysis, adjusted for potential confounding
variables (patient age and sex). Compared to subjects who were
homozygous for the GM 17 allele, the GM 3 homozygotes were
over twice as likely (OR= 2.82), and the GM 3/17 heterozygotes
were over three times as likely (OR= 3.13) to develop glioma.
Likewise, when comparing the combined GM 3/3+ 3/17 (i.e., GM
3-carriers) genotypes to the GM 17/17 genotypes, the presence of
the GM 3 allele conferred a significantly increased risk for glioma
(OR= 2.95) and high-grade astrocytoma (OR= 3.11).
A multivariate Cox proportional hazard model, adjusted for
patient age and sex, was used to investigate the association between
GM genotypes and overall survival. Glioblastoma patients carry-
ing the GM 17/17 genotype had longer median overall survival
(35 months) than patients carrying the GM 3/17 or GM 3/3
genotypes (16 months), but the difference was not statistically sig-
nificant, probably a reflection of small sample size (HR= 2.78,
p= 0.19).
These results support the hypothesis that GM 3 and GM 17
alleles are risk factors for glioma (25). They also shed light on the
possible reasons behind the racial differences in the prevalence of
glioma. Age-adjusted glioma rates are considerably higher in Cau-
casians than in people of African descent. As noted earlier, the GM
3 allele is absent or extremely rare in people with unmixed African
ancestry.
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CYTOMEGALOVIRUS AND UNCOMMON GM GENOTYPES
ASSOCIATED WITH NEUROBLASTOMA
Almost four decades ago, two very unusual GM genotypes,
1+3+21−5+ and 1+3+21+5−, were shown to be highly sig-
nificantly (p< 0.00005) associated with susceptibility to neurob-
lastoma, the most common extracranial solid tumor of child-
hood (26). The mechanism underlying this association has not
yet been elucidated. However, a recent report documenting the
expression of early and late HCMV proteins in primary neurob-
lastomas, neuroblastoma cell lines, and neuroblastoma xenografts
(27) shed some light on the paradox: how a common virus (preva-
lence ~80%) could be associated with an uncommon (prevalence
~0.025%) disease. It is noteworthy that both uncommon geno-
types associated with neuroblastoma include GM 3, the allele
associated with high affinity to the HCMV TRL11/IRL11-encoded
FcγR. To gain further mechanistic insights into the GM gene
involvement in the pathogenesis of this malignancy, it would be
necessary to evaluate the affinity of viral FcγRs to the IgG proteins
expressing other GM alleles – 1, 5, and 21 – that constitute the
genotypes associated with neuroblastoma.
GM ALLELES, CYTOMEGALOVIRUS, AND THE RISK OF
BREAST CANCER
Using a matched case–control design, we have evaluated the con-
tribution of GM alleles to the risk of breast cancer in a large (1710
subjects) multiethnic study population from Japan and Brazil (28).
The study subjects were typed for several GM alleles – IgG1 (3, 17),
IgG2 (23+/−), and IgG3 (5, 21). Conditional logistic regression
models were constructed to detect the association between GM
alleles and breast cancer.
After adjusting for the potential confounders, the GM 3 allele
of IgG1 was significantly associated with susceptibility to breast
cancer in Caucasian subjects from Brazil (p= 0.0147); subjects
possessing this allele were over twice as likely to develop breast
cancer as those who lacked this allele (OR= 2.07). No significant
associations were found in other population groups. The reasons
for racial differences in disease associations are not clear. Link-
age disequilibrium between GM alleles in the Japanese is different
from that in people of African or European descent, resulting in
distinct arrays of GM haplotypes in various groups. It follows
that linkage disequilibrium between any putative risk-conferring
genes for breast cancer and GM alleles might also be different
in these groups, contributing to the ethnic differences in genetic
associations. Multiple genetic and non-genetic factors probably
contribute to the risk of breast cancer, and racial differences in
these factors may contribute to the differences in the observed
associations. It is relevant to note that, of the four population
groups examined, the frequency of the high affinity (to HCMV–
FcγR) GM 3 allele was the highest in the subjects of Caucasian
descent (Brazil).
As in glioma and neuroblastoma, increasing evidence impli-
cates HCMV in the etiopathogenesis of breast cancer. Evidence of
viral expression has been found in over 97% of neoplastic breast
epithelium (29). These findings were confirmed and extended in
a recent investigation, which found 100% of the primary breast
cancer samples HCMV positive, and also detected viral protein
expression in neoplastic cells in sentinel lymph node metastases of
breast cancer (30). Our finding of a significant association between
the GM 3 allele and susceptibility to breast cancer, which is con-
sistent with the predictions from the IgG1–HCMV–FcγR binding
studies (7), appears to unite the putative genetic and viral etiology
of this malignancy.
OTHER MECHANISMS OF GM GENE INVOLVEMENT IN
CANCER
So far, we have discussed how GM alleles could contribute to the
risk of glioma, neuroblastoma, and breast cancer by modulating
the viral immunoevasion strategies. However, this is unlikely to be
the only mechanism underlying their involvement in these malig-
nancies. These determinants could also contribute to the disease
risk by influencing antibody responsiveness to the relevant viral
and tumor-associated antigens. In a recent study, we found the
levels of IgG antibodies to HCMV glycoprotein B to be the highest
in GM 17/17 homozygotes, intermediate in GM 3/17 heterozy-
gotes, and the lowest in GM 3/3 homozygotes (31). If anti-HCMV
antibodies were protective, subjects with the low responder geno-
type – GM 3/3 – would be expected to be at a higher risk of
developing HCMV-associated diseases than the subjects with the
high responder GM 17/17 genotype, a prediction supported by
our finding of GM 3 association with glioma and breast cancer
discussed above. We have also reported contribution of GM alleles
to humoral immunity to some tumor-associated antigens rele-
vant to these malignancies, e.g., human epidermal growth factor
receptor 2 (HER2) and mucin 1 (32, 33).
Although GM allotypes are expressed in the constant region
of γ chains, they could influence antibody specificity and affinity
by imposing structural constraints (conformation) on the variable
region. It is relevant to note that amino acid sequence polymor-
phism in the CH1 domain of the γ1 chain – where the allelic
determinants GM 3 and GM 17 are located – has been shown to
modulate the kinetic competence of antigen binding sites (34).
Another mechanism of GM gene involvement in cancer patho-
genesis could involve ADCC, a major host immunosurveillance
mechanism against tumors and virally infected cells. IgG anti-
body mediated ADCC is triggered upon ligation of FcγR to the
Fc region of IgG molecules, where the majority of GM alleles are
expressed. It follows that genetic variation in FcγR and Fc could
contribute to the differences in the magnitude of ADCC. We have
presented evidence of interactive effects of GM and FcγRIIIa alle-
les on ADCC of cancer cells overexpressing HER1, HER2, mucin
1, and the disialoganglioside antigen GD2 (35–37).
GM GENES AND GENOME-WIDE ASSOCIATION STUDIES
Genome-wide association studies (GWAS) do not evaluate GM
genes and, therefore, none of the GM gene–disease associa-
tions that were identified by hypothesis driven candidate gene
approaches have been confirmed or refuted by these studies.
GM genes are not included in the genotyping platforms com-
monly used in GWAS. Since these genes were not typed in the
HapMap and 1000 Genomes projects, they cannot be imputed.
Genes encoding IgG subclasses that harbor GM alleles are highly
homologous and apparently not amenable to the high throughput
genotyping technologies. This attribute may have contributed to
their exclusion from the genotyping panels.
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FUTURE STUDIES
For a thorough understanding of the underlying immunogenetic
mechanisms in HCMV-associated diseases, further studies are
warranted. A brief outline of some of these follows. The IgG–
HCMV–FcγR binding studies discussed above employed the
HCMV strain AD169 for cloning the TRL11 sequences. Whether
or not TRL11-encoded FcγR from another strain would have the
same affinity for allotypically disparate IgG1 proteins needs to be
investigated. Additional studies to measure binding between allo-
typically different IgG2 and IgG3 proteins and HCMVTRL11- and
UL119-encoded FcγRs are warranted. In this context, it would
be interesting to evaluate the recently described HCMV RL13-
encoded FcγR (38) for its binding affinity to allotypically disparate
IgG proteins.
In view of the strong linkage disequilibrium between particu-
lar GM alleles within a racial group, all GM alleles that constitute
racially associated haplotypes must be evaluated to obtain a more
complete understanding of the contribution of GM alleles to
the risk of malignant diseases discussed above. Future studies
should also consider examining possible interactive contribution
of particular candidate genes to the risk of developing glioma,
neuroblastoma, and breast cancer. Genes do not act in isolation:
there is increasing evidence that epistasis – modification of the
action of a gene by one or more other genes – plays a significant
role in human diseases (39–41). GM and HLA are excellent candi-
date genes for investigations of epistasis in these malignancies, as
both are targets of HCMV immunoevasion strategies (7, 42) and
have been associated with the risk of these cancers (25, 26, 28, 43–
45). Results of these investigations may identify novel pathways
to cancer immunity, which would be helpful in devising effective
immunotherapeutic strategies against these malignancies.
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